Janet Soul

Janet Soul, M.D.

Associate in Neurology; Director, Fetal-Neonatal Neurology Program

Associate Professor of Neurology, Harvard Medical School

  • Contact: 617-355-8994

  • Fax: 617-730-0279

"The broad goal of my research is to understand the causes of these brain injuries and to detect them at their earliest onset in order to develop and test neuroprotective therapies that prevent or minimize brain injury."

Medical Services

Specialties

  • Neurology
  • Fetal-Neonatal Neurology

Departments

  • Neurology

Languages

  • English
  • French

Programs

  • Fetal-Neonatal Neurology Program
  • Advanced Fetal Care Center
  • Infant Follow-Up Program
To schedule an appointment: Call 617-355-8994 or Request an Appointment

Experience and Education

Education

Medical School

McGill University Faculty of Medicine, 1991

Montreal, CANADA

Internship

Boston City Hospital, 1992

Boston, MA

Residency - Pediatrics

Boston City Hospital, 1994

Boston, MA

Fellowship - Neurology

Boston Children's Hospital, 1997

Boston, MA

Fellowship - Neonatal Neurology

Boston Children's Hospital, 1998

Boston, MA

Certifications

  • Pediatrics, Child Neurology

  • American Board of Neurology and Psychiatry: Neurology with Special Qualification in Child Neurology

  • Royal College of Physicians and Surgeons of Canada Neurology

  • American Board of Pediatrics

Professional History

I am a pediatric neurologist whose area of clinical expertise and research is in Fetal and Neonatal Neurology with a focus on the etiology, pathogenesis, outcome and prevention of early acquired brain injury. I direct the Fetal-Neonatal Neurology Program that provides specialized care to fetuses, newborns and children with neurologic disorders that begin in utero or in the neonatal period. This program, with its associated clinical services, provides specialized training for neurology, neonatology and pediatric fellows and residents.  My research and writing are focused on early acquired brain injury, particularly hypoxic-ischemic brain injury, involving a lack of oxygen and blood flow to the brain; the treatment of seizures in term newborns; and periventricular leukomalacia (injury to the white matter of the brain), intraventricular hemorrhage (bleeding into the ventricles of the brain) and hydrocephalus in preterm newborns. I am the PI for a randomized, double-blind, controlled trial of bumetanide for the treatment of neonatal seizures, funded by an R01 from NINDS (NS066929), which is the first to study a novel drug (bumetanide) with an anticonvulsant mechanism specific to the newborn brain.  The broad goal of my research is to understand the causes of these brain injuries and to detect them at their earliest onset in order to develop and test neuroprotective therapies that prevent or minimize brain injury.

To schedule an appointment: Call 617-355-8994 or Request an Appointment

Locations

View Location:

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close